Aripiprazole induced hiccups

2013 ◽  
Vol 3 (3) ◽  
pp. 119-121 ◽  
Author(s):  
Rania Kattura ◽  
Prakeh Shet
Keyword(s):  
Adverse Event ◽  
Causal Relationship ◽  
Case Reports ◽  
Medication Regimen ◽  
Intercostal Muscles ◽  
Spasmodic Contraction ◽  
Environmental Causes

Hiccups are a product of involuntary, intermittent spasmodic contraction of the diaphragm and inspiratory intercostal muscles that results in sudden inspiration and abrupt closure of the glottis. The exact pathophysiology of hiccups remains unknown. However, certain neurotransmitters, medications, and other factors have been implicated. We report a case of a 38 year old patient who developed hiccups three days after adding aripiprazole 5 mg once a day to his medication regimen. Medical and environmental causes were ruled out and aripiprazole was discontinued. One day later, the hiccups resolved. Several case reports have described patients who developed hiccups when treated with aripiprazole and related this to changes in neurotransmitter concentrations. However, due to limited literature, it was difficult to determine rate of occurrence of this adverse event with aripiprazole. A temporal but not a causal relationship was observed between initiating aripiprazole and development of hiccups in this patient. A causal relationship cannot be established since the patient was not re-challenged with aripiprazole. Nonetheless, clinicians should be cognizant that use of aripiprazole may be associated with hiccups.

Evaluation of the Modified Naranjo Criteria for Assessing Causal Attribution of Clinical Outcome to Homeopathic Intervention as Presented in Case Reports

Homeopathy ◽  
2020 ◽  
Vol 109 (04) ◽  
pp. 191-197
Author(s):  
Chetna Deep Lamba ◽  
Vishwa Kumar Gupta ◽  
Robbert van Haselen ◽  
Lex Rutten ◽  
Nidhi Mahajan ◽  
...  
Keyword(s):  
Clinical Outcome ◽  
Causal Relationship ◽  
Clinical Case ◽  
Assessment Tool ◽  
Causal Attribution ◽  
Case Reports ◽  
Face Validity ◽  
Rater Agreement ◽  
The Face ◽  
Selection Of

Abstract Objectives The objective of this study was to establish the reliability and content validity of the “Modified Naranjo Criteria for Homeopathy—Causal Attribution Inventory” as a tool for attributing a causal relationship between the homeopathic intervention and outcome in clinical case reports. Methods Purposive sampling was adopted for the selection of information-rich case reports using pre-defined criteria. Eligible case reports had to fulfil a minimum of nine items of the CARE Clinical Case Reporting Guideline checklist and a minimum of three of the homeopathic HOM-CASE CARE extension items. The Modified Naranjo Criteria for Homeopathy Inventory consists of 10 domains. Inter-rater agreement in the scoring of these domains was determined by calculating the percentage agreement and kappa (κ) values. A κ greater than 0.4, indicating fair agreement between raters, in conjunction with the absence of concerns regarding the face validity, was taken to indicate the validity of a given domain. Each domain was assessed by four raters for the selected case reports. Results Sixty case reports met the inclusion criteria. Inter-rater agreement/concordance per domain was “perfect” for domains 1 (100%, κ = 1.00) and 2 (100%, κ = 1.00); “almost perfect” for domain 8 (97.5%, κ = 0.86); “substantial” for domains 3 (96.7%, κ = 0.80) and 5 (91.1%, κ = 0.70); “moderate” for domains 4 (83.3%, κ = 0.60), 7 (67.8%, κ = 0.46) and 9 (99.2%, κ = 0.50); and “fair” for domain 10 (56.1%, κ = 0.38). For domains 6A (46.7%, κ = 0.03) and 6B (50.3%, κ = 0.18), there was “slight agreement” only. Thus, the validity of the Modified Naranjo Criteria for Homeopathy tool was established for each of its domains, except for the two that pertain to direction of cure (domains 6A and 6B). Conclusion The Modified Naranjo Criteria for Homeopathy—Causal Attribution Inventory was identified as a valid tool for assessing the likelihood of a causal relationship between a homeopathic intervention and clinical outcome. Improved wordings for several criteria have been proposed for the assessment tool, under the new acronym “MONARCH”. Further assessment of two MONARCH domains is required.

International comparison of the quality of voluntary adverse event reports for cremophor-containing paclitaxel-associated anaphylaxis submitted to regulatory agencies in the United States, Europe, and Japan

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 6589-6589
Author(s):  
E. Calhoun ◽  
D. Raisch ◽  
H. Luu ◽  
E. Carias ◽  
L. Irizarry ◽  
...  
Keyword(s):  
Adverse Event ◽  
Adverse Drug Events ◽  
Case Reports ◽  
The United States ◽  
Adverse Event Report ◽  
H2 Blockers ◽  
The Us ◽  
Drug Regimens ◽  
Prophylaxis Therapy

6589 Background: Serious adverse drug events (sADEs) are a significant cause of morbidity and mortality. The FDA's MedWatch program is a voluntary adverse drug reporting program. In Europe and Japan, sADE reports are rarely reimbursed. We evaluated the quality of adverse events reporting in the US, Europe, and Japan for paclitaxel-associated anaphylaxis. Hypersensitivity reactions (presumably due to the diluent cremophor) occur in up to 42% of patients receiving paclitaxel (cremophor- containing paclitaxel was licensed in 1992, a cremophor-free paclitaxel was licensed in 2005). Methods: We reviewed reports of anaphylactic reactions to paclitaxel reported between 1997–2007 contained in the FDA Adverse Event Report System (AERS). Results: Of 171 unique case reports, 34% resulted in death. Cases that resulted in death were mostly incomplete in reporting descriptions of anaphylaxis symptoms and prophylaxis/therapy drug regimens in the US, Europe and Japan. (Table) The median duration between date of event and regulatory notification was 27, 55, and 18 days for the US, Europe, and Japan respectively. Conclusions: Overall, the quality of case reports of serious anaphylaxis reactions to cremophor-containing paclitaxel was poor in the US, Europe, and Japan, despite a substantial number of these reports being associated with death. Surprisingly, among the patients receiving prophylaxis with corticosteroids, anti-histamines, and/or H2-blockers, 36% of patients still died. [Table: see text] No significant financial relationships to disclose.

Little-known Swiss contributions to the description, diagnosis, and surgery of lumbar disc disease before the Mixter and Barr era

2013 ◽  
Vol 19 (6) ◽  
pp. 767-773 ◽  
Author(s):  
Martin Nikolaus Stienen ◽  
Werner Surbeck ◽  
Ulrich Tröhler ◽  
Gerhard Hildebrandt
Keyword(s):  
Causal Relationship ◽  
Case Reports ◽  
Early Report ◽  
Lumbar Disc ◽  
Historical Context ◽  
Traumatic Rupture ◽  
Disc Disease ◽  
Lumbar Disc Disease ◽  
Herniated Lumbar Disc ◽  
Lumbar Spinal

The understanding of lumbar spine pathologies made substantial progress at the turn of the twentieth century. The authors review the original publication of Otto Veraguth in 1929 reporting on the successful resection of a herniated lumbar disc, published exclusively in the German language. His early report is put into the historical context, and its impact on the understanding of pathologies of the intervertebral disc (IVD) is estimated. The Swiss surgeon and Nobel Prize laureate Emil Theodor Kocher was among the first physicians to describe the traumatic rupture of the IVD in 1896. As early as 1909 Oppenheim and Krause published 2 case reports on surgery for a herniated lumbar disc. Goldthwait was the first physician to delineate the etiopathogenes is between annulus rupture, symptoms of sciatica, and neurological signs in his publication of 1911. Further publications by Middleton and Teacher in 1911 and Schmorl in 1929 added to the understanding of lumbar spinal pathologies. In 1929, the Swiss neurologist Veraguth (surgery performed by Hans Brun) and the American neurosurgeon Walter Edward Dandy both published their early experiences with the surgical therapy of a herniated lumbar disc. Veraguth's contribution, however, has not been appreciated internationally to date. The causal relationship between lumbar disc pathology and sciatica remained uncertain for some years to come. The causal relationship was not confirmed until Mixter and Barr's landmark paper in 1934 describing the association of sciatica and lumbar disc herniation, after which the surgical treatment became increasingly popular. Veraguth was among the first physicians to report on the clinical course of a patient with successful resection of a herniated lumbar disc. His observations should be acknowledged in view of the limited experience and literature on this ailment at that time.

scholarly journals Comparison of Rhabdomyolysis Associated With Sacubitril/valsartan-related Drug-drug Interactions by Individual Statins in an Adverse Event Reporting System

2021 ◽  
Author(s):  
Tomiko Sunaga ◽  
Ryo Yonezawa
Keyword(s):  
Adverse Event ◽  
Drug Interactions ◽  
Reporting System ◽  
Case Reports ◽  
Organic Anion ◽  
Adverse Event Reporting System ◽  
Adverse Event Reporting ◽  
Reporting Odds Ratio ◽  
Event Reporting ◽  
Structured Analysis

Abstract BackgroundSacubitril/valsartan was approved in Japan recently. Sacubitril is an inhibitor of organic anion-transporting polypeptide (OATP) 1B1 and 1B3. In Japan, sacubitril/valsartan product labeling indicates that it should be cautiously co-administered with atorvastatin due to drug-drug interactions (DDIs). However, all statins are the substrates of OATP1B1 and/or 1B3. Therefore, we should be cautious about DDIs between sacubitril/valsartan and all other statins.ObjectiveTo evaluate the association between rhabdomyolysis and concomitant association of sacubitril/valsartan with atorvastatin and all other statins.MethodsCase reports from the U.S. Food and Drug Administration’s Adverse Event Reporting System (FAERS) from 2015 to Q4/2020 were used. All FAERS reports on sacubitril/valsartan were captured through a structured analysis. We compared the proportion of cases reporting the adverse events associated with rhabdomyolysis and the concomitant use of sacubitril/valsartan and atorvastatin to those with sacubitril/valsartan and all other statins.ResultsAmong 10,940 case reports on sacubitril/valsartan, compared with all other drugs, statin users were associated with increased rhabdomyolysis (reporting odds ratio =4.54[2.62-7.87]). However, compared with all other statins, atorvastatin was not associated with increased rhabdomyolysis. ConclusionsWe suggest that the co-administration of sacubitril/valsartan with atorvastatin as well as other statins should be carefully managed as it may induce rhabdomyolysis.

Sciatic nerve injury in children after gluteal intramuscular injection: Case reports on medical malpractice

2019 ◽  
Vol 59 (3) ◽  
pp. 139-142
Author(s):  
Peipei Zhuo ◽  
Dong Gao ◽  
Qing Xia ◽  
Dan Ran ◽  
Wentao Xia
Keyword(s):  
Sciatic Nerve ◽  
Causal Relationship ◽  
Nerve Injury ◽  
Medical Malpractice ◽  
Intramuscular Injection ◽  
Case Reports ◽  
Standard Of Care ◽  
Sciatic Nerve Injury ◽  
Foot Drop ◽  
Medical Negligence

Two cases of medical malpractice for sciatic nerve injury caused by gluteal intramuscular injection in China are reported. Two children presented with foot drop indicative of sciatic nerve injury following gluteal intramuscular injections. The appraisal of whether there was medical negligence, the causal relationship between the patients’ nerve injuries and medical standard of care, and the causative potency were entrusted to us by the court. Based on each patient’s original medical history, imaging examination results, limb dysfunction and interviews with their relatives, there was a causal relationship between the children’s injuries and the medical treatment. The causative potency of medical negligence was complete effect in one case and main effect in the other case.

Isotretinoin and Psychiatric Illness in Adolescents and Young Adults

2003 ◽  
Vol 37 (7-8) ◽  
pp. 1124-1127 ◽  
Author(s):  
Shelly J Enders ◽  
Jason M Enders
Keyword(s):  
Young Adults ◽  
Causal Relationship ◽  
Psychiatric Illness ◽  
Case Reports ◽  
Data Sources ◽  
Adolescents And Young Adults ◽  
Data Synthesis ◽  
Primary Literature ◽  
Key Terms ◽  
The Relationship

OBJECTIVE: To evaluate the relationship between isotretinoin and psychiatric illness in adolescents and young adults. DATA SOURCES: Primary literature located via MEDLINE (1966–December 2002). Key terms were isotretinoin, depression, psychosis, suicide, and adolescents. DATA SYNTHESIS: Information regarding depression was added to isotretinoin labeling in 1998 following a series of case reports and submitted to the MedWatch system. CONCLUSIONS: Although a causal relationship may exist between isotretinoin and psychiatric illness in adolescents and young adults, this has not been demonstrated in the literature. Until evidence establishes a presence or lack of causality, prescribers should exercise caution when treating adolescents and young adults with isotretinoin.

Rifabutin-Associated Uveitis

1995 ◽  
Vol 29 (11) ◽  
pp. 1149-1155 ◽  
Author(s):  
Alice L Tseng ◽  
Sharon L Walmsley
Keyword(s):  
Adverse Event ◽  
Drug Interactions ◽  
English Language ◽  
Case Reports ◽  
Data Extraction ◽  
Signs And Symptoms ◽  
Medline Search ◽  
Concurrent Therapy ◽  
Study Selection ◽  
Tolerance Study

Objective: To review rifabutin-associated uveitis and discuss the mechanism and potential role of drug interactions with clarithromycin and fluconazole in contributing to this adverse event. Data Sources: A MEDLINE search (1991 through September 1994) of English-language literature using the main MeSH headings “rifabutin” and “uveitis” and the subheadings “adverse effects” and “chemically induced.” Relevant articles also were selected from references of identified articles. Abstracts from recent medical conferences of infectious diseases, pharmacology, and HIV were screened for additional data. Study Selection and Data Extraction: All articles and abstracts reporting uveitis potentially related to rifabutin were considered for inclusion. Fifty-four cases were identified. Pertinent information from the case reports, as judged by the authors, was selected and synthesized for discussion. Data Synthesis: Rifabutin is being prescribed increasingly for the treatment and prophylaxis of Mycobacterium avium complex (MAC) infection in the HIV-infected population. Uveitis was initially thought to be a rare, dose-limited complication of rifabutin therapy. In an early dose-ranging tolerance study, uveitis was associated with daily doses of 1200 mg or more. Because this toxicity appeared to be dose-related, lower dosages (300–600 mg/d) of rifabutin were selected for study in subsequent clinical trials. More recent reports noting the association of uveitis with these lower dosages of rifabutin have raised concerns about the prevalence of this adverse event. In the 54 identified cases, patients presented with symptoms of unilateral or bilateral uveitis from 2 weeks to more than 7 months following initiation of rifabutin therapy. In all reported cases, patients were receiving concurrent therapy with clarithromycin and/or fluconazole, both of which have inhibitory effects on rifabutin metabolism. In most cases, uveitis resolved within 1–2 months following discontinuation of rifabutin with or without administration of topical corticosteroids. Conclusions: Rifabutin is prescribed frequently for the prophylaxis and treatment of MAC infection, especially in patients with HIV. Uveitis is a rare, dose-related toxicity of this therapy. The risk of rifabutin-associated uveitis may be increased in patients receiving concurrent therapy with clarithromycin or fluconazole because of drug interactions. Patients receiving therapy with combinations of any of these agents should be warned about signs and symptoms of uveitis and be monitored closely for the development of rifabutin toxicity. If uveitis develops, rifabutin therapy should be discontinued promptly.

scholarly journals The association between varicella (chickenpox) and group A streptococcus infections in historical perspective

2016 ◽  
Vol 4 ◽  
pp. 205031211665890 ◽  
Author(s):  
Stephen Coleman
Keyword(s):  
New York ◽  
Causal Relationship ◽  
Scarlet Fever ◽  
Group A Streptococcus ◽  
Case Reports ◽  
Empirical Studies ◽  
Strong Relationship ◽  
Close Relationship ◽  
Group A ◽  
The Relationship

Objectives: The aim of the research is to investigate the historical relationship between varicella and Streptococcus pyogenes infections. In the past few decades, varicella has been identified as a risk factor for invasive group A streptococcus infections. The question is whether this relationship also existed between varicella and scarlet fever in the historical era. Methods: The analysis begins with a search of historical medical reports on the relationship between varicella and scarlet fever epidemics in the late 19th and early 20th century, as well as in more recent empirical studies. Correlations and cross-correlations between varicella and scarlet fever are analyzed using weekly public health case reports from 1924 to 1932 for Boston, Chicago, New York City, and Philadelphia. Regression models are used to estimate the relationship between varicella and scarlet fever after controlling for seasonal forcing. Results: Historical records give limited support for a causal relationship between varicella and scarlet fever but indicate that these diseases often occurred close in time to each other. Likewise, statistical analysis shows that varicella and scarlet fever epidemics are closely aligned with each other, and varicella has a strong relationship with scarlet fever. The relationship is stronger than reported in any previous research on the two diseases. Conclusion: The close correspondence of the two diseases likely depends on multiple factors, including seasonal forcing, a causal relationship, and co-infections. The results raise questions about whether this close relationship might have had a synergistic effect or a role in the evolution of S. pyogenes from the virulent, high incidence epidemics of the 19th century to the relatively benign scarlet fever of the 1950s.

Brodalumab for Treatment-Resistant Psoriasis: Case Reports and Safety Update

2020 ◽  
Vol 5 (3) ◽  
pp. 82-85
Author(s):  
Nicholas D. Brownstone ◽  
Vidhatha Reddy ◽  
Quinn Thibodeaux ◽  
Stephanie Chan ◽  
Bridget Myers ◽  
...  
Keyword(s):  
Causal Relationship ◽  
Drug Administration ◽  
Safety Profile ◽  
Case Reports ◽  
Food And Drug Administration ◽  
Black Box ◽  
Interleukin 17 ◽  
Treatment Resistant ◽  
Effective Agent ◽  
Increased Risk

Introduction: Brodalumab is an interleukin-17 receptor blocker that is effective for the treatment of psoriasis. However, due to a Food and Drug Administration black box warning on depression and suicide, many providers are hesitant to use this agent despite its efficacy. Methods: We present the cases of 2 brothers seen at our clinic with treatment-resistant psoriasis who were both successfully treated with brodalumab, despite failing 6 other biologics. We also review the safety profile of brodalumab regarding the currently available evidence on the increased risk of suicidality or depression in patients treated with brodalumab. Results: Both patients achieved completely clear skin and maintained clearance on brodalumab. Discussion: Brodalumab appears to be an effective agent in severe treatment-resistant cases of psoriasis. In addition, a causal relationship between increased risk of suicidality or depression and brodalumab use has not been established.

Sign in / Sign up

Export Citation Format

Share Document